Barclays PLC Aldeyra Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 65,561 shares of ALDX stock, worth $317,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,561

Previous 65,561 -0.0%

Holding current value

$317,970

Previous $353,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.19 - $6.32 $154,118 - $305,338	48,313 Added 280.11%	65,561 $353,000
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $49,526 - $71,928	-15,239 Reduced 46.91%	17,248 $57,000
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $86,889 - $132,372	-31,368 Reduced 49.12%	32,487 $106,000
Q4 2023 Feb 15, 2024	SELL	$1.47 - $6.06 $109,450 - $451,203	-74,456 Reduced 53.83%	63,855 $224,000
Q3 2023 Nov 07, 2023	BUY	$6.11 - $8.16 $69,941 - $93,407	11,447 Added 9.02%	138,311 $924,000
Q2 2023 Aug 03, 2023	BUY	$7.11 - $11.89 $782,377 - $1.31 Million	110,039 Added 654.02%	126,864 $1.07 Million
Q1 2023 May 04, 2023	SELL	$5.77 - $9.93 $74,744 - $128,633	-12,954 Reduced 43.5%	16,825 $167,000
Q4 2022 Feb 13, 2023	BUY	$5.08 - $7.09 $105,887 - $147,783	20,844 Added 233.28%	29,779 $207,000
Q3 2022 Nov 03, 2022	BUY	$3.8 - $7.74 $33,953 - $69,156	8,935 New	8,935 $48,000
Q2 2022 Aug 12, 2022	SELL	$2.43 - $4.85 $366,883 - $732,257	-150,981 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $299,234 - $476,012	92,072 Added 156.3%	150,981 $671,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $52,598 - $144,719	15,028 Added 34.25%	58,909 $236,000
Q3 2021 Nov 09, 2021	BUY	$7.94 - $11.31 $120,576 - $171,753	15,186 Added 52.92%	43,881 $386,000
Q2 2021 Aug 13, 2021	SELL	$10.44 - $14.85 $230,202 - $327,442	-22,050 Reduced 43.45%	28,695 $325,000
Q1 2021 May 13, 2021	BUY	$6.53 - $14.42 $331,364 - $731,742	50,745 New	50,745 $603,000
Q3 2020 Nov 12, 2020	SELL	$4.0 - $7.53 $25,804 - $48,576	-6,451 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$1.97 - $5.05 $2,304 - $5,908	-1,170 Reduced 15.35%	6,451 $27,000
Q1 2020 May 13, 2020	SELL	$1.62 - $6.4 $24,794 - $97,952	-15,305 Reduced 66.76%	7,621 $19,000
Q4 2019 Feb 10, 2020	BUY	$4.73 - $7.98 $55,516 - $93,661	11,737 Added 104.9%	22,926 $133,000
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $14,782 - $20,514	-3,352 Reduced 23.05%	11,189 $59,000
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $38,052 - $57,078	6,342 Added 77.35%	14,541 $87,000
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $12,559 - $17,326	1,759 Added 27.31%	8,199 $74,000
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $529 - $970	73 Added 1.15%	6,440 $53,000
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $35,353 - $74,605	5,199 Added 445.12%	6,367 $88,000
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $8,110 - $10,713	1,167 Added 116700.0%	1,168 $9,000
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $6 - $8	1 New	1 $0
Q4 2017 Feb 14, 2018	SELL	$5.7 - $7.75 $19,380 - $26,350	-3,400 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $13,260 - $36,720	3,400	3,400 $24,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account